Pharma Co. Misled Investors On Seizure Drug Trial, Suit Says

By Sydney Price · June 6, 2024, 8:13 PM EDT

Marinus Pharmaceuticals has been hit with a proposed shareholder class action alleging that the company understated the risks of an epilepsy drug trial and did not warn investors that trial enrollment...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

BISHINS v. MARINUS PHARMACEUTICALS, INC. et al

Case Number

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Securities/Commodities

Date Filed

June 05, 2024

Recent Articles By Sydney

July 02, 2024
Pharma Co. Scores Exit In Investor Suit Over Primate Imports
May 15, 2024
UnitedHealth Concealed DOJ Merger Investigation, Suit Says
May 13, 2024
Biogen Investors Seek Class Cert. In Alzheimer's Drug Suit
May 08, 2024
Shockwave Medical Investor Challenges $13B Deal With J&J
May 07, 2024
Pharma Co. Falsely Touted Obesity Drug Results, Suit Claims
May 06, 2024
Judge Trims ESOP Valuation Suit Against Healthcare Co.
April 29, 2024
AI Pharma Co. Sued By Investor Over Handling Of Fired CEO
April 23, 2024
GoodRx Hid Revenue Reliance On Kroger, Suit Claims
April 03, 2024
Healthcare Company Hid Rising Costs Before IPO, Suit Says
April 01, 2024
Pharma Co. Beats Investor Suit Over Wrinkle Drug Approval